BiotechTube

BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis

Trial Timeline

May 17, 2021 → Sep 21, 2022

NCT ID
NCT04544943

About BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin

BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin is a phase 1 stage product being developed by Hoth Therapeutics for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT04544943. Target conditions include Atopic Dermatitis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04544943Phase 1Completed

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85

Other Products from Hoth Therapeutics

HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 PlaceboPhase 2
44